Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Clin Cancer Res. 2018 Sep 10;25(2):663–673. doi: 10.1158/1078-0432.CCR-18-0926

Figure 3. Combination therapy with FGFR and COX-2 inhibitors restores sensitivity to MET inhibitors in resistant GBM cells.

Figure 3.

U87 wild type (WT), crizotinib-resistant (CR) & Onartuzumab-resistant (OR) cells were pretreated with A). COX-2 inhibitor celecoxib (100 nM) or B). FGFR1 inhibitor Debio-1347 (10 μM) for 2 hr then subsequently treated with either crizotinib (100 nM) or Onartuzumab (Onart) (300 nM) for 48 hr. Cell death was assessed via trypan blue assay. U87 WT, CR & OR cells were pretreated with C). & D). Celecoxib or E). & F). Debio-1347 for 2 hrs then subsequently treated with either crizotinib (100 nM) or Onart (300 nM) for 48 hr. Cell proliferation was assessed by cell counting over a period of 5 days and growth curves were established. *, P < 0.05.